Immunocore FY2026 Earnings Forecast Reduced by HC Wainwright

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR – Free Report) – Equities research analysts at HC Wainwright lowered their FY2026 earnings per share (EPS) estimates for shares of Immunocore in a research note issued to investors on Tuesday, November 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.26) per share for the year, down from their previous forecast of $0.11. HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Immunocore’s Q4 2026 earnings at ($0.22) EPS, FY2028 earnings at $1.81 EPS, FY2029 earnings at $4.15 EPS and FY2030 earnings at $6.98 EPS.

A number of other equities analysts have also issued reports on IMCR. Morgan Stanley decreased their target price on shares of Immunocore from $43.00 to $42.00 and set an “equal weight” rating for the company in a research report on Friday. JPMorgan Chase & Co. started coverage on shares of Immunocore in a research note on Friday, August 21st. They set an “overweight” rating and a $50.00 target price on the stock. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Zacks Research lowered shares of Immunocore from a “hold” rating to a “strong sell” rating in a research note on Monday, November 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Immunocore currently has an average rating of “Hold” and a consensus target price of $52.86.

Get Our Latest Analysis on Immunocore

Immunocore Price Performance

Shares of NASDAQ IMCR opened at $29.94 on Thursday. Immunocore has a fifty-two week low of $27.50 and a fifty-two week high of $40.71. The firm’s 50-day simple moving average is $31.07 and its 200 day simple moving average is $31.63. The company has a quick ratio of 4.44, a current ratio of 4.62 and a debt-to-equity ratio of 0.94. The stock has a market cap of $1.54 billion, a P/E ratio of -46.06 and a beta of 0.82.

Immunocore (NASDAQ:IMCR – Get Free Report) last released its quarterly earnings results on Friday, November 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.11). The business had revenue of $102.22 million during the quarter, compared to the consensus estimate of $152.09 million. Immunocore had a negative return on equity of 7.96% and a negative net margin of 7.48%.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in Immunocore by 202.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,920 shares of the company’s stock valued at $61,000 after acquiring an additional 1,286 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Immunocore during the 3rd quarter valued at about $72,000. Juncture Wealth Strategies LLC acquired a new position in shares of Immunocore in the 3rd quarter worth approximately $207,000. denkapparat Operations GmbH acquired a new position in shares of Immunocore in the 2nd quarter worth approximately $209,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Immunocore by 27.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,252 shares of the company’s stock worth $285,000 after purchasing an additional 1,975 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

About Immunocore

(Get Free Report)

Immunocore is a biotechnology company that develops T cell receptor (TCR)-based medicines for cancer and other diseases. Its ImmTAX platform is designed to create therapies that direct the body’s T cells toward targets inside cells, including targets that may be difficult for conventional antibody treatments to reach. The company’s marketed medicine, KIMMTRAK (tebentafusp-tebn), is a TCR-based therapy approved in the United States and other markets for certain patients with unresectable or metastatic uveal melanoma.

Recommended Stories

Earnings History and Estimates for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.